Lee’s Pharmaceutical Posts Strong Mid-Year Growth

Lee’s Pharmaceutical Holdings Limited (HK:0950) has released an update.

Lee’s Pharmaceutical Holdings Limited reported a significant revenue increase of 28.5% in the first half of 2024, reaching HK$658,345,000, driven by strong sales performances of products on the National Reimbursement Drug List. The company also saw a substantial rise in profit, attributable to owners, by 287.7%, and a leap in earnings per share, showcasing the firm’s robust growth amid industry challenges. This financial growth underscores the company’s ability to navigate market pressures and capitalize on the demand for its key pharmaceutical products.

For further insights into HK:0950 stock, check out TipRanks’ Stock Analysis page.